Earnings season's real number is the bridge between adjusted and reported

Strong quarters, split screens

The headline picture this season is good. BioMarin grew third-quarter revenue 32% to $1.025 billion. Tarsus posted XDEMVY net product sales of $194.6 million, up about 64%. Xeris grew total revenue 44% to $107 million and lifted its 2030 outlook to more than $1 billion from roughly $750 million. TG Therapeutics raised full-year revenue guidance to about $1 billion from about $950 million. Charles River and iRhythm both raised their guides too.

But the results carry a second layer that the headlines flatten. Adjusted and reported figures are telling different stories, and they are doing so in both directions. CompePharma's view is that the quality of an earnings print now depends on how well a company explains that gap, more than on whether it beat.

The bridge is where the information sits

Take Charles River. Non-GAAP earnings per share were $3.09, up 27.2%, yet GAAP earnings per share were $6.86, well above the adjusted figure. GAAP operating margin rose 730 basis points to 20.6%, against a 330-basis-point rise to 23.0% on the non-GAAP measure. Adjusted numbers normally flatter. Here they sit well below the reported figure, and anyone modelling the business needs the reconciliation to know why.

iRhythm runs the other way. Revenue rose 14.9% to $221.6 million, gross margin reached 74.2%, and adjusted EBITDA margin improved by 1,190 basis points to 23.1%. Yet the GAAP net loss was $29.9 million, $24.6 million worse than a year earlier. Both statements are true. A reader who sees only one of them has the wrong picture of the business.

Guidance has the same problem. Charles River attributed its raise primarily to third-quarter outperformance, led by DSA and a lower tax rate. A tax rate is not demand. BioMarin's updated guide explicitly reflects order timing uncertainty and two acquired IPR&D charges. Those are different kinds of movement, and they should not be netted into one number and called a raise or a trim.

The strongest counter-argument

The case against this view is serious. Adjusted metrics exist because acquired IPR&D charges, tax effects and timing items obscure the run-rate of a commercial business. Executives and investors who want to know whether Tarsus or TG can sustain growth do not want a quarter distorted by an accounting event. Forcing every discussion back to GAAP can bury the signal in noise.

That is fair, and nobody should abandon adjusted figures. But the argument has a limit. When a company's strategy includes repeated acquisitions, as BioMarin's does after buying Amicus Therapeutics and then flagging two acquired IPR&D charges, those charges are a cost of the growth model, not an anomaly. Excluding them is defensible only if the company also shows what they bought and what they cost. The same applies to a tax-rate tailwind, which helps this year's earnings but says nothing about next year's demand.

What leaders should do

Treat the reconciliation as a product. Put it on the first page of the release and the first slide of the call, and say which items recur. If a guidance change comes from operations, say so. If it comes from tax, timing or acquisition accounting, split it out and label it.

This matters more in a season where growth is genuinely good. Companies with strong underlying results have the most to gain from transparency, because it lets the market separate their durable growth from their accounting. Those who leave the gap unexplained invite the market to assume the worst about it.

— The Editor, CompePharma